Alliance was founded in 1996 by John Dawson (CEO) and began trading in 1998. Since then the company has grown consistently with a strong acquisition and value extraction programme.
Alliance acquired the rights to Nizoral® in 15 territories in APAC from Johnson & Johnson
Acquired the global rights to Vamousse® from TyraTech. Vamousse® strengthens our European base and provides the opportunity for us to expand our affiliate base into the US.
Ametop Gel 4% w/w
Acquired rights to Ametop® from global medical technology business Smith & Nephew. Ametop® is an established product that adds to our growing dermatology business
Sinclair Healthcare Products
Acquired Sinclair IS Pharma plc's healthcare products business consisting a portfolio of 27 products and including operations in Paris & Milan.
Acquired UK based MacuVision Europe Limited, including its MACUSHIELD® eye care brand. The MACUSHIELD® range of food supplements is supplied in the form of daily capsules containing lutein, zeaxanthin and meso-zeaxanthin.
Acquired the rights to IRENAT™ from subsidiaries of Bayer AG. IRENAT™, an established prescription product, is marketed in Germany and provided the first business for our German operating company.
Acquired the UK and Republic of Ireland rights to LYPSYL®, a well-known lip-care brand, from Novartis Consumer Health. This provided another addition to our growing consumer healthcare portfolio.
Acquired all existing rights to SYNTOMETRINE®, an obstetric drug used in the final stage of child-birth, from Novartis Pharma AG. With sales in many countries world-wide including Australia, South Africa, Malaysia and New Zealand, this significantly boosted our international sales.
Acquired Opus Healthcare Group, a UK-based supplier of stoma care products, taking us into a new therapy area.
Paludrine, Avloclor and Savarine
Acquired the worldwide rights to the antimalarial brands PALUDRINE®, AVLOCLOR® and SAVARINE® from AstraZeneca UK Limited, leading to the creation of our French operating company.
Quinoderm and Ceanel
Acquired the UK rights to the brands QUINODERM® and CEANEL® from Ferndale Pharmaceuticals Limited. QUINODERM® is an OTC acne treatment and CEANEL® is a shampoo used in the treatment of scalp psoriasis.
Beacon Pharmaceuticals Limited
Acquired the UK rights to six products from Beacon Pharmaceuticals Limited. The majority of these sales and margin for this portfolio relates to RIZUDERM® (isotretinoin), which is used in the treatment of severe acne.
Anbesol and Ashton & Parsons
Acquired the UK and Irish rights to the brands ANBESOL® and ASHTON & PARSONS® from Reckitt Benckiser. ANBESOL® is used to treat mouth ulcers, teething pains and denture irritation. ASHTON & PARSONS® is used in infants for the symptomatic relief of pain and stomach upset caused by teething.
Acquired the trade and certain assets of Cambridge Laboratories, to include a portfolio of 18 products, including two promoted oncology brands.
Buccastem and Timodine
Acquired worldwide rights to the brands BUCCASTEM® for nausea and vomiting and TIMODINE® for severe nappy rash from Reckitt Benckiser.
Acquired the brand PAVACOL-D®, a sugar-free cough suppressant that is suitable for use by diabetics from William Ransom & Sons.
Acquired the rights to market FORCEVAL® in China and the Far East, through entering into a joint venture with a local distributor, increasing our international presence and giving us a point of entry into this important high growth territory.
Acquired the UK rights to SYNTOMETRINE® from Novartis. Alliance had previously marketed and distributed SYNTOMETRINE® in the UK since 1998 under a distribution agreement.
Acquired PERMITABS® in the UK and the Republic of Ireland for the treatment of infected wounds and skin conditions from Derma UK.
Acquired the well-established oral steroid DELTACORTRIL®, the oral anti-histamine ATARAX® and TERRACORTRIL® from Pfizer, giving Alliance the UK rights to additional products for our dermatology range and other indications.
Acquired the UK rights to DERMAMIST®, a cutaneous spray used for dry skin conditions, from Caraderm and further complementing our existing dermatology range.
Acquired the UK rights to HYDROMOL®, a family of cream, emollient and ointment products for various dry skin conditions such as eczema, bringing critical mass to our dermatology portfolio.
No new acquisitions this year as we were busy integrating acquisitions made in late 2004.
Acquired the assets of Unigreg Ltd giving Alliance significant UK turnover and an international network of distributors with FORCEVAL®, a multivitamin and mineral food supplement.
Acquired the rights to PERIOSTAT®in the UK, Europe and various international territories from CollaGenex Inc .
Acquired Dermapharm Ltd, gaining the rights to four niche dermatologicals.
Alliance on the London Stock Exchange
No new acquisitions this year as most of our time was taken up with the floatation of the company on the Alternative Investment Market (AIM) of the London Stock Exchange.
Expanded into the Republic of Ireland with the acquisition of the rights to NU-SEALS® from Eli Lilly and Company.
Alphaderm and Aquadrate
Acquired the rights to the dermatology brands ALPHADERM® and AQUADRATE® from Procter and Gamble.
Symmetrel and Slow-K
Acquired the territory rights to SYMMETREL® and SLOW-K® from Novartis.
Acquired the rights to DISTAMINE® from Eli Lilly.
Naseptin, Broflex, Biorphen and Pragmatar
Alliance acquired the rights to NASEPTIN®, BROFLEX®, BIORPHEN® and PRAGMATAR from Bioglan.
Arrangement with Novartis
Alliance entered into a fostering arrangement with Novartis and took over the marketing and distribution of 16 speciality prescription brands.